Home
overview
The Aims & Objectives of the Conference

Moving forward within the 21st century, more and more pharmaceutical companies are increasing research and development into pain management. Although pain is not a life-threatening disease, pain therapeutics play are immensely important to the healthcare system.

Our third Pain Therapeutics event promises to be as successful as the first two and will address the very latest advances in pain research. This event will cover areas such as use of molecular targets for pain drug discovery, identification of the mode of action of existing successful drugs, results from transgenic animals, safety concerns over COX-2 inhibitors and the market position for pain therapeutics. Economic, regulatory and legal issues of prime importance to the industry will also be discussed. The conference aims to bring together leaders in the fields of pain, medicine, and drug development to offer an insight into developments in pain therapeutics and to analyse the future directions for the industry.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Guy Seabrook

Dr Guy Seabrook, Project Director, Merck Sharpe & Dohme

9:10 INTRODUCTION TO PAIN

Dr Steven England

Dr Steven England, Principal Scientist, Pfizer

  • Market opportunity
  • Issues with existing therapies
  • Unmet medical need
  • Key factors for success of new compounds
  • Major obstacles to success
  • 9:40 PAIN MANAGEMENT

    Dr Phillip Birch

    Dr Phillip Birch, Chief Scientific Officer, Ionix Pharmaceuticals

  • Epidemiology and market segmentation
  • Current treatments for chronic pain
  • Emerging therapies
  • The role of drug delivery technology in pain management
  • The search for new analgesics
  • 10:20 CURRENT RESEARCH IN PAIN THERAPEUTICS

    Dr Zahid Ali

    Dr Zahid Ali, Senior Research Pharmacologist, Merck Sharpe & Dohme

  • Molecular targets in pain research
  • Research methodologies
  • Tools for pain research
  • Current pain drugs and therapeutic modalities
  • New targets for pain relief ligands
  • 11:00 Morning Coffee

    11:20 PHARMACOLOGICAL PAIN MANAGEMENT

    Dr Barbara Schneider

    Dr Barbara Schneider, Director, Clinical Development, Kendle

  • New approaches to improve pain management
  • Treatments for chronic pain
  • Different types of treating pain
  • Different types of drug delivery in pain management
  • Future pain management techniques
  • 12:00 DEVELOPMENTS

    Dr Terry Smith

    Dr Terry Smith, Development Director, CeNeS

  • Traditional opiates
  • New developments
  • M6G
  • Pain relief
  • Current trends and research
  • Future pain management techniques
  • 12:40 Lunch

    14:00 PAEDIATRIC PAIN

    Dr Robert Medve

    Dr Robert Medve, Senior Director, Johnson & Johnson

  • Historical context
  • Current challenges
  • Defining the population
  • Research methods
  • Ethical principles
  • The way forward
  • 14:40 NEUROPATHIC PAIN

    Dr Mark Field

    Dr Mark Field, Senior Principal Scientist, Pfizer

  • What is neuropathic pain
  • How does neuropathic pain differ from other types of pain
  • Current treatments for neuropathic pain
  • Preclinical models of neuropathic pain – assessment of pain subtypes
  • Future opportunities
  • 15:20 Afternoon Tea

    15:40 CHRONIC PAIN

    Dr Tony Priestley

    Dr Tony Priestley, Associate Director, Schering Plough

  • Common chronic pain syndromes
  • Preclinical animal models
  • Current pharmacotherapeutic
  • Efficacy vs. tolerability
  • New therapeutic approaches and future opportunities
  • 16:20 NEUROPATHIC PAIN

    Dr James Sullivan

    Dr James Sullivan, Divisional Vice President, Neuroscience, Abbott

  • Development of unique, pain controlling therapies
  • An understanding of how neuropathic pain differs from other types of pain
  • Understanding the underlying mechanisms of neuropathic pain
  • New molecular approaches to the treatment of neuropathic pain
  • Different kinds of treatment
  • New and emerging trends
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Najob Babul

    Dr Najob Babul, Director, Pain, TheraQuest

    9:10 MIGRAINE PAIN

    Dr Jenny Longmore

    Dr Jenny Longmore, Pain, Migraine Research, Merck Sharpe & Dohme

  • Development of unique, pain controlling therapies
  • An understanding of how neuropathic pain differs from other types of pain
  • Understanding the underlying mechanisms of migraine pain
  • Different kinds of treatment
  • New and emerging trends
  • 9:40 ANALGESIA STRATEGIES

    Dr Andy Dray

    Dr Andy Dray, Scientific Director, AstraZeneca

  • Overview mechanisms of acute and chronic pain
  • Pain as disease what are the causes and pathophysiological substrates?
  • What are the best target families for novel analgesia approaches?
  • Focus on G protein coupled receptors: why?
  • Some current initiatives: opioids receptors, cannabinoid receptors, sensory neurone specific receptors
  • 10:20 FIBROMYALGIA SYNDROME

    Dr Graham Birrell

    Dr Graham Birrell, Business Development Manager, Intercern

  • Definition of FMS
  • Neurophysiological basis of fibromyalgia pain
  • Assessment of fibromyalgia pain
  • Current therapies
  • Clinical studies
  • Potential future drug therapies
  • 11:00 Morning Coffee

    11:20 OPIOID ANALGESIA

    Prof. Tony Rees

    Prof. Tony Rees, Director, Science, Synt:em

  • Central delivery using peptrans vectors
  • Rapid and extended analgesia
  • No respiratory depression
  • Effective in inflammatory models
  • Attractive pharmacodynamic profile
  • 12:00 VANILLOID RECEPTORS AND NOCICEPTION

    Dr Peter McIntyre

    Dr Peter McIntyre, Laboratory Head & Programme Team Head, Novartis

  • Expression of vanilloid receptors
  • Function of cloned VR1
  • Comparison of VR1 receptors from different species
  • VR1 as a pivotal transducer
  • Related receptors
  • 12:40 Lunch

    13:40 THE DEVELOPMENT OF INTRATHECAL ANALGESICS IN REFRACTORY PAIN

    Dr David Ellis

    Dr David Ellis, Medical Director, Elan

  • Overview of intrathecal analgesia
  • Summary of ziconotide pharmacology
  • Challenges in the design of intrathecal trials
  • Patients with refractory pain
  • Analgesic efficacy of ziconotide
  • Safety profile of intrathecal ziconotide
  • 14:20 ANALGESIC DRUG DEVELOPMENT IN THE MULTIDOSE AND CHRONIC PAIN SETTING

    Dr Najib Babul

    Dr Najib Babul, Chief Executive Officer, TheraQuest

  • Current challenges with multidose evaluation in acute pain
  • Solutions for multidose analgesic evaluation in acute pain
  • Selection of chronic pain models for pain studies
  • Endpoint selection in chronic pain
  • Key study design consideration in chronic pain
  • Future opportunities
  • 15:00 MOLECULAR TARGETS

    Prof. Praveen Anand

    Prof. Praveen Anand, Professor, Clinical Neurology & Head, Peripheral Neuropathy Unit, Imperial College of Science, Technology & Medicine, Hammersmith Hospital

  • Distribution of key ion channels, receptors, neuroeffectors
  • Inducible enzymes and their products
  • Human tissue studies in common pain states
  • How do animal models relate to human data?
  • How can we increase success of Phase II clinical trials?
  • 15:40 Afternoon Tea

    16:00 NOVEL DRUG DISCOVERIES

    Dr Bradley Galer

    Dr Bradley Galer, Vice President, Scientific Affairs, Endo Pharmaceuticals

  • · Opioid-sparing · Tolerance · Neuropathic pain qualities
  • Novel drug delivery in neuropathic pain · Targeted peripheral analgesia
  • 16:30 NEUROPATHIC PAIN

    Dr Susanne Begley

    Dr Susanne Begley, Head, Central Nervous System, Datamonitor

  • Current market overview
  • Pipeline analysis
  • The Pfizer factor: neurontin and pregablin
  • Potential impact of anticonvulsant trial failures
  • Improving the analgesia: the short term future of the market
  • Treating the underlying cause: the long term goal
  • 17:10 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Critial Issues in Pain Trials for the Elderly
    Workshop

    Critial Issues in Pain Trials for the Elderly

    The Hatton, at etc. venues
    12th June 2002
    London, United Kingdom

    Clinical Quantitative Sensory Testing
    Workshop

    Clinical Quantitative Sensory Testing

    The Hatton, at etc. venues
    12th June 2002
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.